NCT06840002RecruitingPhase 1/2
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
An Open, Multicenter Phase Ib / II Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
Source: ClinicalTrials.gov · Last updated 11 Sept 2026
Brief summary (registry, in English)
The objective is to evaluate the tolerance, safety, pharmacokinetic characteristics and immunogenicity of SHR-A1811 combined with carboplatin and bevacizumab in the treatment of platinum sensitive recurrent epithelial ovarian cancer, and to determine the RP2D of the combination, and preliminarily to evaluate the effectiveness of SHR-A1811 combined regimen in the treatment of platinum sensitive recurrent epithelial ovarian cancer.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 17 Feb 2025
- Start date
- 18 Mar 2025
- Primary completion date
- Dec 2026
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Diseases
- Ovarian cancer
- NCT number
- NCT06840002
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 150
- From 18 Mar 2025 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous interstitial pneumonia or interstitial lung disease, non infectious pneumonia requiring steroid treatment.
- Subjects with serious infection within 1 month before the first medication.
Other illness
- With untreated or active central nervous system (CNS) tumor metastasis. Subjects with a history of meningeal metastasis or current meningeal metastasis.
- With hypertension and cannot be well controlled by antihypertensive drug treatment.
- Accompanied by poorly controlled or serious cardiovascular diseases.
- Have a history of immune deficiency, including HIV test positive, other acquired or congenital immune deficiency diseases, or a history of organ transplantation.
- There are any other factors that may affect the results of the study or cause the forced termination of the study, such as alcohol abuse, drug abuse, criminal detention, and other serious diseases (including mental illness) that need combined treatment.
Other
- Pleural effusion, pericardial effusion or peritoneal effusion with clinical symptoms, which cannot be well controlled.
Who the study is looking for
- Voluntarily join this study, sign the informed consent form, have good compliance, and can cooperate with the follow-up.
- Sufficient fresh or archived tumor tissue specimens can be provided for testing by the third-party central laboratory designated by the sponsor.
- At least one measurable lesion conforming to RECIST v1.1.
- ECOG PS score: 0-1.
- Expected survival ≥ 12 weeks.
- Female subjects with fertility must agree to comply with the contraceptive requirements from signing the informed consent form to 7 months after the last administration of the trial drug.
Age in the registry: 18 years to 75 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology Coordinator of this site? Confirm its status | Wuhan | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.